Trijardy XR 25 mg/1

Trijardy XR 25 mg/1 is a combination medication containing empagliflozin, linagliptin, and metformin hydrochloride. It is designed to help manage type 2 diabetes by improving blood sugar control. This extended-release tablet is taken orally and is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.

Trijardy XR 25 mg/1 is primarily used for the management of type 2 diabetes in adults. It works by combining three active ingredients to help control blood sugar levels. Empagliflozin, linagliptin, and metformin hydrochloride each play a role in improving glycemic control. This medication is often prescribed as part of a comprehensive treatment plan that includes diet and exercise.

Common effects of Trijardy XR 25 mg/1 may include gastrointestinal issues such as diarrhea, nausea, and vomiting. Some users might experience headaches or dizziness. It is important to monitor blood sugar levels regularly while taking this medication. Always consult a healthcare provider for personalized advice.

Trijardy XR 25 mg/1 should be handled with care. It is important to follow the prescribed dosage and administration instructions. Patients with certain medical conditions, such as kidney or liver problems, should discuss their health status with a healthcare provider before starting this medication. Always store the medication in a cool, dry place away from direct sunlight.

Trijardy XR 25 mg/1 may interact with other medications, including certain antibiotics, antifungal agents, and HIV medications. Alcohol consumption should be avoided as it can increase the risk of side effects. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.